Table 2. Co-occurrence of IL7Ra, JAK1 and/or JAK3, and N-RAS, K-RAS and/or NF1 mutations with unsupervised gene expression profile clusters or T-ALL subtypes.

T-ALL subtype	IL7Ra cysteine mutations (n=7)		JAK1 and/or JAK3 mutations (n=9)		N-RAS, K-RAS and/or NF1 mutations (n=20)
		P-value		P-value		P-value
ETP-ALL (n=15)	0 (0%)	0.59	3 (20.0%)	0.09	6 out of 13 (46.2%)	0.016
TLX (n=30)	6 (20.0%)	0.001	4 (13.3%)	0.23	9 out of 27 (33.3%)	0.044
Proliferative (n=19)	0 (0%)	0.60	1 (5.3%)	1	0 out of 17 (0%)	0.038
TALLMO (n=53)	1 (1.9%)	0.13	1 (1.9%)	0.039	5 out of 48 (10.4%)	0.047
Total (n=117)	7 (6.0%)		9 (7.7%)		20 (17.1%)

Abbreviations: T-ALL, T-cell acute lymphoblastic leukemia. The bold is used for significant values. Note: we reported previously that PTEN and AKT mutations predominantly fall in the TALLMO subgroup.^{41, 42}